Lupin has received tentative approval from the Food and Drug Administration for raltegravir tablets, 600 mg, which is a ...

In the September quarter, the pharma major’s US sales dipped sequentially to $220 million against $227 million in Q1FY25.

CEO Vinita Gupta stated that Lupin expects to maintain a quarterly range of $220-230 million for its US business, driven by ...

Lupin Q2 Results Live : Lupin declared their Q2 results on November 7, 2024, reporting a robust performance with a topline ...

Ramesh Swaminathan, Global CFO of Lupin discusses the impact of Trump's win on the Indian pharmaceutical sector. Growing ...

Prabhudas Lilladher is bullish on Lupin has recommended buy rating on the stock with a target price of Rs 2420 in its ...

Macquarie analysts described the results as an "all-round beat". Although revenue aligned closely with their forecast, Ebitda ...

Lupin’s 2QFY25 EBITDA/Adj PAT were 18%/26% ahead of our estimates (the magnitude of beat was broadly similar vs street ...

When you buy through links on our articles, Future and its syndication partners may earn a commission.

Shares of the Lupin Ltd. traded at Rs 2095.25 on BSE at 11:10AM (IST) on Monday, down 0.43 per cent. The stock quoted a ...

Warner Bros. Discovery is adapting the Harry Potter novels all over again – this time as a TV series – and it’s hard to ...

Seinen series like Akira, Ghost in the Shell, Berserk, Vagabond, and Kingdom are staples in dark fantasy and historical epics ...